The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study

https://pubmed.ncbi.nlm.nih.gov/39118050/ The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study In this study, researchers adapted an existing, validated, discrete-event simulation model to extend the published RxPONDER trial data to estimate long-term, population-level breast cancer outcomes in women diagnosed with HR+, HER2-, node-positive (1–3 nodes) breast cancer with a RS of ≤ 25. The overarching goal of this study was to extend trial results to estimate population-level outcomes and support the integration of trial findings into clinical practice. Author: Kaitlyn M. Wojcik*, Jennifer L. Caswell-Jin, Oliver W. A. Wilson*, Clyde Schechter, Dalya Kamil*, Allison W. Kurian, and Jinani Jayasekera Journal: BMC Cancer, August 8